CSF-NfL correlates to MRI progression in MS, a 10-year follow-up study
ECTRIMS Online Library. Bhan A. 09/11/19; 278952; P592
Alok Bhan
Alok Bhan
Contributions
Abstract

Abstract: P592

Type: Poster Sessions

Abstract Category: Pathology and pathogenesis of MS - Biomarkers

A. Bhan1, E. Farbu1, G. Alves1, C. Jacobsen1, K.-M. Myhr2

1Department of Neurology, Stavanger University Hospital, Stavanger, 2Neurology, Haukeland University Hospital, Bergen, Norway

Introduction: The need for a prognostic biomarker in multiple sclerosis (MS) is imminent. Neurofilament light (NfL) is a promising biomarker in disease follow-up, but longitudinal data regarding its prognostic value is still scarce.
Objectives: To evaluate the long-term prognostic value of NfL in cerebrospinal fluid (CSF) at time of diagnosis of MS with respect to brain volume loss as assessed by magnetic resonance imaging (MRI) over a course of 10 years of follow-up.
Methods: Newly diagnosed patients with MS between 1998 and 2000 in South-Western Norway participated in this prospective study. CSF NfL was measured at baseline using the commercially available Uman Diagnostic NF-light ® ELISA kit. Cerebral MRI was performed at baseline, 5 years and 10 years on 1.5 T scanners to calculate T1-lesion and T2-lesion volumes (LVs). Global and regional atrophy changes were longitudinally assessed using a direct measurement approach, by calculating percentage volume changes between different time points. Regional tissue volumes for the subcortical deep grey matter (SDGM) structures were also obtained.
Results: 44 patients participated at baseline, 39 patients after 5 years and 27 patients after 10 years of follow-up. At 5 years there was a significant correlation between baseline NfL and percentage total brain volume change from baseline (r=-0.464, p=0.003) and percentage deep grey matter volume change (r=-0.430, p=0.006), of which change in putamen volume (r=-0.411, p=0.009), hippocampus volume (r=-0.459, p=0.003) and thalamus volume (r=-0.572, p=0.021) correlated significantly. At 10 years there was a significant correlation between baseline NfL and percentage total brain volume change (-0.395, p=0.042) and deep grey matter volume change (r=-0.395, p=0.041), of which change in pallidal nuclei volume (r=-0.445, p=0.020) and hippocampus volume (r=-0.472, p=0.013) correlated significantly.
Discussion: CSF NfL levels at baseline correlate with MRI progression over a 10-years disease course in newly diagnosed MS patients.
Disclosure:
Alok Bhan: Has received an unrestricted research grant from Novartis.
Kjell-Morten Myhr: Has served on scientific advisory boards
from Novartis Norway, Biogen Idec, Genzyme, and
Roche; received speaker honoraria from Genzyme,
Sanofi-Aventis, Novartis, Biogen Idec, and Teva; and
received unrestricted research support from Sanofi-
Aventis, Novartis, Biogen Idec, and the Norwegian
MS Society.

Cecilie Jacobsen: Has received an unrestricted research grant from Novartis.
Elisabeth Farbu: Participated in advisory boards and received honoraria as speaker from Novartis, Sanofi Genzyme, Biogen, Merck.

Guido Alves: Has nothing to disclose.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies